Indaptus Therapeutics
INDP
15 hedge funds and large institutions have $6.81M invested in Indaptus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
0.06% less ownership
Funds ownership: 0.8% → 0.74% (-0.06%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
35% less capital invested
Capital invested by funds: $10.5M → $6.81M (-$3.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$175K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$124K |
| 3 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$110K |
| 4 |
State Street
Boston,
Massachusetts
|
+$89.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$47.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$917K |
| 2 |
Millennium Management
New York
|
-$217K |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$16K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.45K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.28K |
INDP Hedge Fund Activity: Q1 2022 in Review
15 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2022, worth a combined $6.81M — down 35% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new INDP positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $175K. The largest seller was Stratos Wealth Partners, cutting an estimated $917K.
- 15 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2022, up from 14 in Q4 2021.
- Funds reported $6.81M of Indaptus Therapeutics stock for Q1 2022, down 35% quarter-over-quarter.
- 5 funds opened new Indaptus Therapeutics positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest Indaptus Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $175K added.
- The largest Indaptus Therapeutics seller in Q1 2022 was Stratos Wealth Partners, an estimated $917K sold.
Based on aggregated 13F filings for Q1 2022.